| Schedule of significant expense categories |
| | | | | | | | | | | | | | | | Three Months Ended June 30, | | Six Months Ended June 30, | | | | 2026 | | 2025 | | 2026 | | 2025 | | Operating Expenses: | | | | | | | | | | | | | | PMN310 development program costs | | $ | 7,785,427 | | $ | 8,050,610 | | $ | 14,049,539 | | $ | 12,776,951 | | Other non-employee research and development costs | | | 310,571 | | | 220,669 | | | 503,285 | | | 498,584 | | Employee costs | | | 2,916,715 | | | 1,053,258 | | | 4,030,478 | | | 2,496,325 | | Other general and administrative costs | | | 1,253,686 | | | 860,124 | | | 2,327,994 | | | 1,872,897 | | Net Operating Loss: | | $ | 12,266,399 | | $ | 10,184,661 | | $ | 20,911,296 | | $ | 17,644,757 | | Other income | | | (536,743) | | | (67,632) | | | (937,267) | | | (179,825) | | Net Loss: | | $ | 11,729,656 | | $ | 10,117,029 | | $ | 19,974,029 | | $ | 17,464,932 | | | | | | | | | | | | | | | | Reconciliation of Loss | | | | | | | | | | | | | | Adjustments and reconciling items | | | — | | | — | | | — | | | — | | Consolidated Net Loss: | | $ | 11,729,656 | | $ | 10,117,029 | | $ | 19,974,029 | | $ | 17,464,932 | | | | | | | | | | | | | | | | |
|